Aloisine A

Inhibitor of CDK and GSK



ALX-270-385-M001	1 mg	36.00 USD

Cell permeable, potent, selective, reversible and ATP-competitive inhibitor of CDK1/cyclin B (IC₅₀=150nM), CDK2/cyclin A (IC₅₀=120nM), CDK2/cyclin E (IC₅₀=400nM), CDK5/p25 (IC₅₀=200nM), CDK5/p35 (IC₅₀=160nM) and GSK-3α (IC₅₀=500nM). Also inhibits GSK-3β (IC₅₀=650nM) and c-Jun N-terminal kinase (JNK) (IC₅₀~3-10µM). Poor inhibitor of CK1, CK2, CDK4/cyclin D1, MAPKK, PKA, PKG, PKCs and c-raf (IC₅₀≥100µM).

Alternative Name:	RP107, 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine

Formula:	C₁₆H₁₇N₃O

MW:	267.3

Purity:	≥95% (HPLC)

Appearance:	Yellow solid.

CAS:	496864-16-5

Solubility:	10mg/ml soluble in DMSO.

Long Term Storage:	-20°C

Handling:	Packaged under inert gas. Protect from light.

Please mouse over

Product Literature References

Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects: Y. Mettey, et al.; J. Med. Chem. 46, 222 (2003), Abstract;